Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports

OBZ appears to be a suitable alternative when other treatment options are ineffective or contraindicated. The efficacy of OBZ for treatment of refractory MN needs to be verified by large-scale multicenter clinical trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-04-15
DOI
https://doi.org/10.3389/fimmu.2025.1561638
Citations
2
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
2.86
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports

Hong Wu, Jinmeng Wang, Wenfeng Wu
2 citations
Frontiers in Immunology
Renal Diseases and Glomerulopathies
2.86
article

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports

Hong Wu, Jinmeng Wang, Wenfeng Wu
article en
2 citations

Abstract

OBZ appears to be a suitable alternative when other treatment options are ineffective or contraindicated. The efficacy of OBZ for treatment of refractory MN needs to be verified by large-scale multicenter clinical trials.

Frontiers in ImmunologyVol. 16
Nanfang Hospital (CN), Southern Medical University (CN)
Good health and well-being
Openalex Percentile: Top 11%
Renal Diseases and Glomerulopathies
2.86
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports — Hong Wu, Jinmeng Wang, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS